Indications and Usage:
Adults
Vesfol is indicated as an addition to a low-calorie diet and vigorous exercise for long-term use to correct body weight in adult patients with BMI:
- ≥30 kg/m2 (obesity) or
- ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity such as prediabetes, type 2 diabetes mellitus, arterial hypertension, dyslipidaemia or obstructive sleep apnoea syndrome.
Adolescents
Vesfol may be used as an adjunct to a healthy diet and increased physical activity to correct body weight in adolescents aged 12 years and older with:
- body weight over 60 kg and
- obesity (BMI corresponding to ≥30 kg/m2 for adults according to international thresholds)*.
*IOTF BMI threshold for obesity by sex in ages 12 to 18 years.
Table 1. IOTF BMI threshold for obesity by sex in ages 12 to 18 years.
|
Age |
BMI |
|
|
Male |
Female |
|
|
12 |
26,02 |
26,67 |
|
12,5 |
26,43 |
27,24 |
|
13 |
26,84 |
27,76 |
|
13,5 |
27,25 |
28,20 |
|
14 |
27,63 |
28,57 |
|
14,5 |
27,98 |
28,87 |
|
15 |
28,30 |
29,11 |
|
15,5 |
28,60 |
29,29 |
|
16 |
28,88 |
29,43 |
|
16,5 |
29,14 |
29,56 |
|
17 |
29,41 |
29,69 |
|
17,5 |
29,70 |
29,84 |
|
18 |
30,00 |
30,00 |
Regulatory Status: Rx only.
Not included in the Essential Drug List (EDL).
THERE ARE CONTRAINDICATIONS AND DRUG INTERACTIONS. PLEASE CONSULT A SPECIALIST BEFORE USE.
For the full version of the Vesfol (liraglutide) leaflet, please visit this website: https://grls.rosminzdrav.ru/Default.aspx
at all stages of production
